WO2021079196A3 - Mettl3 modulators - Google Patents
Mettl3 modulators Download PDFInfo
- Publication number
- WO2021079196A3 WO2021079196A3 PCT/IB2020/001135 IB2020001135W WO2021079196A3 WO 2021079196 A3 WO2021079196 A3 WO 2021079196A3 IB 2020001135 W IB2020001135 W IB 2020001135W WO 2021079196 A3 WO2021079196 A3 WO 2021079196A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mettl3
- modulators
- compounds
- formula
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080088790.7A CN115298179A (en) | 2019-10-21 | 2020-10-20 | METTL3 modulators |
EP20862016.1A EP4048674A2 (en) | 2019-10-21 | 2020-10-20 | Mettl3 modulators |
JP2022523855A JP2022553077A (en) | 2019-10-21 | 2020-10-20 | METTL3 modulator |
AU2020372002A AU2020372002A1 (en) | 2019-10-21 | 2020-10-20 | Mettl3 modulators |
US17/770,708 US20230027361A1 (en) | 2019-10-21 | 2020-10-20 | Mettl3 modulators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962923936P | 2019-10-21 | 2019-10-21 | |
US62/923,936 | 2019-10-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2021079196A2 WO2021079196A2 (en) | 2021-04-29 |
WO2021079196A3 true WO2021079196A3 (en) | 2021-07-01 |
WO2021079196A9 WO2021079196A9 (en) | 2022-07-14 |
Family
ID=73856560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2020/001135 WO2021079196A2 (en) | 2019-10-21 | 2020-10-20 | Mettl3 modulators |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230027361A1 (en) |
EP (1) | EP4048674A2 (en) |
JP (1) | JP2022553077A (en) |
CN (1) | CN115298179A (en) |
AU (1) | AU2020372002A1 (en) |
WO (1) | WO2021079196A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022074391A1 (en) * | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
CN113234079B (en) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | Nucleoside analogs as PRMT5 inhibitors |
CN114032311A (en) * | 2021-12-24 | 2022-02-11 | 山东大学齐鲁医院 | Application of METTL3 in AML chemotherapy resistance |
WO2023151697A1 (en) * | 2022-02-11 | 2023-08-17 | 四川海思科制药有限公司 | Mettl3 inhibitor and composition, and application of same in medicine |
CN115850280A (en) * | 2022-12-08 | 2023-03-28 | 南京康立瑞生物科技有限公司 | Preparation method of antiviral drug entecavir intermediate N4 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
WO2019032859A1 (en) * | 2017-08-09 | 2019-02-14 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2019112719A1 (en) * | 2017-12-05 | 2019-06-13 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
-
2020
- 2020-10-20 AU AU2020372002A patent/AU2020372002A1/en active Pending
- 2020-10-20 CN CN202080088790.7A patent/CN115298179A/en active Pending
- 2020-10-20 EP EP20862016.1A patent/EP4048674A2/en active Pending
- 2020-10-20 JP JP2022523855A patent/JP2022553077A/en active Pending
- 2020-10-20 WO PCT/IB2020/001135 patent/WO2021079196A2/en unknown
- 2020-10-20 US US17/770,708 patent/US20230027361A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
WO2019032859A1 (en) * | 2017-08-09 | 2019-02-14 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2019112719A1 (en) * | 2017-12-05 | 2019-06-13 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU2020372002A1 (en) | 2022-05-26 |
CN115298179A (en) | 2022-11-04 |
WO2021079196A9 (en) | 2022-07-14 |
US20230027361A1 (en) | 2023-01-26 |
WO2021079196A2 (en) | 2021-04-29 |
JP2022553077A (en) | 2022-12-21 |
EP4048674A2 (en) | 2022-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021079196A3 (en) | Mettl3 modulators | |
CR20200553A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
AU2020330570A8 (en) | Process of making CFTR modulators | |
MX2021000887A (en) | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer. | |
AU2018351533A8 (en) | Crystalline forms and compositions of CFTR modulators | |
AU2018271990A1 (en) | Covalent inhibitors of KRAS | |
WO2017176957A8 (en) | Mdm2 protein degraders | |
CR20220258A (en) | Kras g12c inhibitors | |
WO2018086591A8 (en) | Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines | |
MX2022001828A (en) | Crystalline forms of cftr modulators. | |
MX2020009530A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors. | |
WO2017210545A8 (en) | Potassium channel modulators | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
MX2021011606A (en) | Compounds targeting prmt5. | |
MX2022006783A (en) | New methylquinazolinone derivatives. | |
MX2021006695A (en) | Modulators of trex1. | |
WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
CR20200382A (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
MX2022004451A (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases. | |
MX2022004450A (en) | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases. | |
MX2021012105A (en) | Pyrrole compounds. | |
MX2021007247A (en) | Rapamycin derivatives. | |
MX2022006653A (en) | Compounds for modulating activity of fxr and uses thereof. | |
CR20220029A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20862016 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2022523855 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020372002 Country of ref document: AU Date of ref document: 20201020 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020862016 Country of ref document: EP Effective date: 20220523 |